TAGRAXOFUSP + Azacitidine + Venetoclax for neoplasm, residual

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 29 Aug 2025: Trial registered, NCT07148180
  2. 2 Feb 2026: Trial started, NCT07148180

The trials

NCT07148180: A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax

State
Under way
Phase
Phase 1 and Phase 2
People
31 planned
Started
2 Feb 2026
Primary completion
31 Dec 2028
Arms
Arm 1: Phase 1 Dose Escalation, Arm 2: Phase 2 Dose Expansion
Results
None posted
  1. 29 Aug 2025: Trial registered
  2. 2 Feb 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.